LATE COMPLICATIONS AFTER THERAPY IN PATIENT WITH HODGKIN'S LYMPHOMA
During the past five decades, dramatic progress has been made in the development of curative therapy for hematologic malignancies, including Hodgkin’s Lymphoma (HL). The therapy responsible for this survival can also produce adverse long-term health-related outcomes, referred to as «late effects», which manifest months to years after completion of cancer treatment.
The purpose of this report is to pay attention to the problem of late complications, which develop in distant period after combined therapy of HL on example of illustrative clinical case.
Patients, who have been treated for Hodgkin's disease, despite being cured of their malignancy, may develop iatrogenic complications that lead to premature mortality. A substantial excess risk of mortality may be attributable to second cancers and cardiac diseases. Multitude of patients has been treated with anthracyclines or chest radiation, both of which may cause cardiovascular and kidney damage. The frequency of long-term complications in patients treated for Hodgkin's disease makes continued follow-up an important part of their care. This follow-up should include efforts to prevent morbidity and mortality by early diagnosis and attention to risk factors. Future treatment regimens for Hodgkin's disease should be designed attempting to minimize these complications.
Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s Disease / [B. M. Aleman, A. W. van den Belt-Dusebout, W. J. Klokman, et al.] // Journal of Clinical Oncology. – 2003. – P. 3431–3439.
Late Effects of Treatment for Childhood Cancer (PDQ®): Treatment - Health Professional Information [NCI] [electronic resource] // HealthLinkBC. – 2016. – Access to the source: https://www.healthlinkbc.ca/health-topics/ncicdr0000343584.
Hodgkin disease survival in Europe and the U.S.: prognostic significance of morphologic groups / [C. Allemani, M. Sant, R. De Angelis, et al.] // Cancer. – 2006. –No 107. – P. 352–360.
Aging and Risk of Severe, Disabling, Life-Threatening, and Fatal Events in the Childhood Cancer Survivor Study / [G. T. Armstrong, T. Kawashima, W. Leisenring, et al.] // Journal of Clinical Oncology. – 2014. –No 32 (12). – P 1218–1227.
Survivors of Childhood Cancer in the United States: Prevalence and Burden of Morbidity / [S. M. Phillips, L. S. Padgett, W. M. Leisenring, et al.] // Cancer Epidemiol Biomarkers Prev. – 2015. –No 24 (4). –P. 653–663.
Clinical ascertainment of health outcomes among adults treated for childhood cancer / [M. M. Hudson, K. K. Ness, J. G. Gurney, et al.] // JAMA. – 2013. –No 309 (22). – P. 2371–2381.
Copyright (c) 2017 The Journal of V. N. Karazin Kharkiv National University, series "Medicine"
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Journal of V. N. Karazin Kharkiv National University, series Medicine has following copyright terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.